{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T08:02:23Z","timestamp":1765958543746,"version":"3.48.0"},"reference-count":83,"publisher":"Begell House","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Crit Rev Eukaryot Gene Expr"],"published-print":{"date-parts":[[2025]]},"abstract":"<p>The recent trend of translational research has introduced a paradigm shift of our understanding of the applicability of bench top research. Translational research funnels in the outcomes of various techniques used in basic research and utilizes them for the benefit of patients in clinical research. Using the example of multiple myeloma, the aim of this article is to shed light on how our accumulated knowledge in different areas of basic research and application of cutting-edge technologies is leveraged in diagnosis, disease gradation, and prognosis. Patients suffering from this incurable disease benefit from the outcome of this research and experience significantly extended progress-free survival, which was beyond imagination even a few decades ago. The disease is currently managed by well-established and continuously evolving treatment options for patients, thus keeping their hope alive for a permanent cure.<\/p>","DOI":"10.1615\/critreveukaryotgeneexpr.2025060495","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:29:36Z","timestamp":1760027376000},"page":"35-49","source":"Crossref","is-referenced-by-count":0,"title":["Multiple Myeloma: A Continuously Evolving Disease"],"prefix":"10.1615","volume":"35","author":[{"given":"Partha","family":"Mitra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"613","reference":[{"key":"2","doi-asserted-by":"crossref","unstructured":"Clarke SE, Fuller KA, Erber WN. Chromosomal defects in multiple myeloma. Blood Rev. 2024;64:101168.","DOI":"10.1016\/j.blre.2024.101168"},{"key":"3","doi-asserted-by":"crossref","unstructured":"Cardona-Benavides IJ, de Ram\u00f3n C, Guti\u00e9rrez NC. Genetic abnormalities in multiple myeloma: Prognostic and therapeutic implications. Cells. 2021;10(2).","DOI":"10.3390\/cells10020336"},{"key":"4","doi-asserted-by":"crossref","unstructured":"Coluzzi F, Rolke R, Mercadante S. Pain management in patients with multiple myeloma: An update. Cancers. 2019;11(12).","DOI":"10.3390\/cancers11122037"},{"key":"5","doi-asserted-by":"crossref","unstructured":"Sezer O, Vesole DH, Singhal S, Richardson P, Stadtmauer E, Jakob C, Boral AL, Esseltine DL, Mehta J. Bortezomib-induced tumor lysis syndrome in multiple myeloma. Clin Lymphoma Myeloma. 2006;7(3):233-5. doi: 10.3816\/CLM.2006.n.064. PMID: 17229340.","DOI":"10.3816\/CLM.2006.n.064"},{"key":"6","doi-asserted-by":"crossref","unstructured":"Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016;43(6):676-81.","DOI":"10.1053\/j.seminoncol.2016.11.004"},{"key":"7","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Kumar S. Multiple myeloma: Diagnosis and treatment. Mayo Clin Proc. 2016;91(1):101-19.","DOI":"10.1016\/j.mayocp.2015.11.007"},{"key":"8","doi-asserted-by":"crossref","unstructured":"Padala SA, Barsouk A, Barsouk A, Rawla P, Vakiti A, Kolhe R, Kota V, Ajebo GH. Epidemiology, staging, and management of multiple myeloma. Med Sci. 2021;9(1):3. doi: 10.3390\/medsci9010003. PMID: 33498356; PMCID: PMC7838784.","DOI":"10.3390\/medsci9010003"},{"key":"9","doi-asserted-by":"crossref","unstructured":"Gould J, Alexanian R, Goodacre A, Pathak S, Hecht B, Barlogie B. Plasma cell karyotype in multiple myeloma. Blood. 1988;71(2):453-6.","DOI":"10.1182\/blood.V71.2.453.bloodjournal712453"},{"key":"10","doi-asserted-by":"crossref","unstructured":"Hu Y, Chen W, Wang J. Progress in the identification of gene mutations involved in multiple myeloma. Onco Targets Ther. 2019;12:4075-80.","DOI":"10.2147\/OTT.S205922"},{"key":"11","doi-asserted-by":"crossref","unstructured":"Sewify EM, Afifi OA, Mosad E, Zaki AH, El Gammal SA. Cyclin D1 amplification in multiple myeloma is associated with multidrug resistance expression. Clin Lymphoma Myeloma Leuk. 2014;14(3):215-22.","DOI":"10.1016\/j.clml.2013.07.008"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Diamantidis MD, Papadaki S, Hatjiharissi E. Exploring the current molecular landscape and management of multiple myeloma patients with the t(11;14) translocation. Front Oncol. 2022;12:934008.","DOI":"10.3389\/fonc.2022.934008"},{"key":"13","unstructured":"Bal S, Kumar SK, Fonseca R, Gay F, Hungria VT, Dogan A, Costa LJ. Multiple myeloma with t(11;14): Unique biology and evolving landscape. Am J Cancer Res. 2022;12(7):2950-65. PMID: 35968339; PMCID: PMC9360221."},{"key":"14","doi-asserted-by":"crossref","unstructured":"Kleber M, Ntanasis-Stathopoulos I, Terpos E. The Role of t(11;14) in tailoring treatment decisions in multiple myeloma. Cancers. 2023;15(24).","DOI":"10.3390\/cancers15245829"},{"key":"15","doi-asserted-by":"crossref","unstructured":"Troussard X, Avet-Loiseau H, Macro M, Mellerin MP, Malet M, Roussel M, Sola B. Cyclin D1 expression in patients with multiple myeloma. Hematol J. 2000;1(3):181-5. doi: 10.1038\/sj.thj.6200025. PMID: 11920187.","DOI":"10.1038\/sj.thj.6200025"},{"key":"16","doi-asserted-by":"crossref","unstructured":"Jiang Y, Zhang C, Lu L, Wang X, Liu H, Jiang Y, Hong L, Chen Y, Huang H, Guo D. The prognostic role of Cyclin D1 in multiple myeloma: A systematic review and meta-analysis. Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338211065252. doi: 10.1177\/15330338211065252. PMID: 35098809; PMCID: PMC8811435.","DOI":"10.1177\/15330338211065252"},{"key":"17","doi-asserted-by":"crossref","unstructured":"Albero R, Enjuanes A, Demajo S, Castellano G, Pinyol M, Garcia N, Capdevila C, Clot G, Su\u00e1rez-Cisneros H, Shimada M, Karube K, L\u00f3pez-Guerra M, Colomer D, Bea S, Martin-Subero JI, Campo E, Jares P. Cyclin D1 overexpression induces global transcriptional downregulation in lymphoid neoplasms. J Clin Invest. 2018;128(9):4132-47. doi: 10.1172\/JCI96520. Epub 2018 Aug 20. PMID: 29990311; PMCID: PMC6118591.","DOI":"10.1172\/JCI96520"},{"key":"18","doi-asserted-by":"crossref","unstructured":"Flynt E, Bisht K, Sridharan V, Ortiz M, Towfic F, Thakurta A. Prognosis, biology, and targeting of TP53 dysregulation in multiple myeloma. Cells. 2020;9(2).","DOI":"10.3390\/cells9020287"},{"key":"19","doi-asserted-by":"crossref","unstructured":"Martello M, Poletti A, Borsi E, Solli V, Dozza L, Barbato S, Zamagni E, Tacchetti P, Pantani L, Mancuso K, Vigliotta I, Rizzello I, Rocchi S, Armuzzi S, Testoni N, Marzocchi G, Martinelli G, Cavo M, Terragna C. Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma. Blood Cancer J. 2022;12(1):15. doi: 10.1038\/s41408-022-00610-y. PMID: 35082295; PMCID: PMC8791929.","DOI":"10.1038\/s41408-022-00610-y"},{"key":"20","doi-asserted-by":"crossref","unstructured":"Jovanovi\u0107 KK, Escure G, Demonchy J, Willaume A, Van de Wyngaert Z, Farhat M, Chauvet P, Facon T, Quesnel B, Manier S. Deregulation and targeting of TP53 pathway in multiple myeloma. Front Oncol. 2019;8:665. doi: 10.3389\/fonc.2018.00665. PMID: 30687640; PMCID: PMC6333636.","DOI":"10.3389\/fonc.2018.00665"},{"key":"21","doi-asserted-by":"crossref","unstructured":"Teoh PJ, Chng WJ. p53 abnormalities and potential therapeutic targeting in multiple myeloma. Biomed Res Int. 2014;2014:717919.","DOI":"10.1155\/2014\/717919"},{"key":"22","doi-asserted-by":"crossref","unstructured":"Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004;303(5659):844-8. doi: 10.1126\/science.1092472. Epub 2004 Jan 2. PMID: 14704432.","DOI":"10.1126\/science.1092472"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Jones RJ, Bjorklund CC, Baladandayuthapani V, Kuhn DJ, Orlowski RZ. Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA. Mol Cancer Ther. 2012;11(10):2243-53.","DOI":"10.1158\/1535-7163.MCT-12-0135"},{"key":"24","doi-asserted-by":"crossref","unstructured":"Lambert JM, Gorzov P, Veprintsev DB, S\u00f6derqvist M, Segerb\u00e4ck D, Bergman J, Fersht AR, Hainaut P, Wiman KG, Bykov VJ. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell. 2009;15(5):376-88. doi: 10.1016\/j.ccr.2009.03.003. PMID: 19411067.","DOI":"10.1016\/j.ccr.2009.03.003"},{"key":"25","doi-asserted-by":"crossref","unstructured":"Lionetti M, Barbieri M, Todoerti K, Agnelli L, Marzorati S, Fabris S, Ciceri G, Galletti S, Milesi G, Manzoni M, Mazzoni M, Greco A, Tonon G, Musto P, Baldini L, Neri A. Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: Implication for MEK-ERK pathway activation. Oncotarget. 2015;6(27):24205-17. doi: 10.18632\/oncotarget.4434. PMID: 26090869; PMCID: PMC4695180.","DOI":"10.18632\/oncotarget.4434"},{"key":"26","doi-asserted-by":"crossref","unstructured":"Heuck CJ, Jethava Y, Khan R, van Rhee F, Zangari M, Chavan S, Robbins K, Miller SE, Matin A, Mohan M, Ali SM, Stephens PJ, Ross JS, Miller VA, Davies F, Barlogie B, Morgan G. Inhibiting MEK in MAPK pathway-activated myeloma. Leukemia. 2016;30(4):976-80. doi: 10.1038\/leu.2015.208. Epub 2015 Jul 31. PMID: 26228812; PMCID: PMC4832073.","DOI":"10.1038\/leu.2015.208"},{"key":"27","doi-asserted-by":"crossref","unstructured":"Andrulis M, Lehners N, Capper D, Penzel R, Heining C, Huellein J, Zenz T, von Deimling A, Schirmacher P, Ho AD, Goldschmidt H, Neben K, Raab MS. Targeting the BRAF V600E mutation in multiple myeloma. Cancer Discov. 2013;3(8):862-9. doi: 10.1158\/2159-8290.CD-13-0014. Epub 2013 Apr 23. PMID: 23612012.","DOI":"10.1158\/2159-8290.CD-13-0014"},{"key":"28","doi-asserted-by":"crossref","unstructured":"Mey UJM, Renner C, von Moos R. Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation. Hematol Oncol. 2017;35(4):890-3.","DOI":"10.1002\/hon.2353"},{"key":"29","doi-asserted-by":"crossref","unstructured":"Perroud C, Thurian D, Andres M, K\u00fcnzi A, Wiedemann G, Zeerleder S, Bacher U, Pabst T, Banz Y, Porret N, Rebmann E. Effect of MAPK activation via mutations in NRAS, KRAS and BRAF on clinical outcome in newly diagnosed multiple myeloma. Hematol Oncol. 2023;41(5):912-21. doi: 10.1002\/hon.3208. Epub 2023 Jul 15. PMID: 37452600.","DOI":"10.1002\/hon.3208"},{"key":"30","doi-asserted-by":"crossref","unstructured":"Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, Dispenzieri A, Kumar S, Clark RJ, Baris D, Hoover R, Rajkumar SV. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study. Blood. 2009;113(22):5412-7. doi: 10.1182\/blood-2008-12-194241. Epub 2009 Jan 29. PMID: 19179464; PMCID: PMC2689042.","DOI":"10.1182\/blood-2008-12-194241"},{"key":"31","doi-asserted-by":"crossref","unstructured":"Wang C, Wang W, Wang M, Deng J, Sun C, Hu Y, Luo S. Different evasion strategies in multiple myeloma. Front Immunol. 2024;15:1346211. doi: 10.3389\/fimmu.2024.1346211. PMID: 38464531; PMCID: PMC10920326.","DOI":"10.3389\/fimmu.2024.1346211"},{"key":"32","doi-asserted-by":"crossref","unstructured":"Swamydas M, Murphy EV, Ignatz-Hoover JJ, Malek E, Driscoll JJ. Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma. J Hematol Oncol. 2022;15(1):17.","DOI":"10.1186\/s13045-022-01234-2"},{"key":"33","doi-asserted-by":"crossref","unstructured":"Minnie SA, Hill GR. Immunotherapy of multiple myeloma. J Clin Invest. 2020;130(4):1565-75.","DOI":"10.1172\/JCI129205"},{"key":"34","doi-asserted-by":"crossref","unstructured":"Chen C, Baldassarre F, Kanjeekal S, Herst J, Hicks L, Cheung M. Lenalidomide in multiple myeloma-a practice guideline. Curr Oncol. 2013;20(2):e136-49.","DOI":"10.3747\/co.20.1252"},{"key":"35","doi-asserted-by":"crossref","unstructured":"Zelle-Rieser C, Thangavadivel S, Biedermann R, Brunner A, Stoitzner P, Willenbacher E, Greil R, J\u00f6hrer K. T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. J Hematol Oncol. 2016;9(1):116. doi: 10.1186\/s13045-016-0345-3. PMID: 27809856; PMCID: PMC5093947.","DOI":"10.1186\/s13045-016-0345-3"},{"key":"36","doi-asserted-by":"crossref","unstructured":"Liu Z, Xu X, Liu H, Zhao X, Yang C, Fu R. Immune checkpoint inhibitors for multiple myeloma immunotherapy. Exp Hematol Oncol. 2023;12(1):99.","DOI":"10.1186\/s40164-023-00456-5"},{"key":"37","doi-asserted-by":"crossref","unstructured":"Zhao B, Zhao H, Zhao J. Efficacy of PD-1\/PD-L1 blockade monotherapy in clinical trials. Ther Adv Med Oncol. 2020;12:1758835920937612.","DOI":"10.1177\/1758835920937612"},{"key":"38","doi-asserted-by":"crossref","unstructured":"Eroglu Z, Kim DW, Wang X, Camacho LH, Chmielowski B, Seja E, Villanueva A, Ruchalski K, Glaspy JA, Kim KB, Hwu WJ, Ribas A. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. Eur J Cancer. 2015;51(17):2689-97. doi: 10.1016\/j.ejca.2015.08.012. Epub 2015 Sep 10. PMID: 26364516; PMCID: PMC4821004.","DOI":"10.1016\/j.ejca.2015.08.012"},{"key":"39","doi-asserted-by":"crossref","unstructured":"Kamali AN, Hamedifar H, Eisenhut M, Bautista JM. Multiple myeloma and the potential of new checkpoint inhibitors for immunotherapy. Ther Adv Vaccines Immunother. 2024;12:25151355241288453.","DOI":"10.1177\/25151355241288453"},{"key":"40","doi-asserted-by":"crossref","unstructured":"Garderet L, D'Souza A, Jacobs P, van Biezen A, Sch\u00f6nland S, Kroeger N, Morris C, Hari P. Response assessment in myeloma: Practical manual on consistent reporting in an era of dramatic therapeutic advances. Biol Blood Marrow Transplant. 2017;23(7):1193-202. doi: 10.1016\/j.bbmt.2017.03.009. Epub 2017 Mar 8. PMID: 28285082.","DOI":"10.1016\/j.bbmt.2017.03.009"},{"key":"41","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez D, van der Burg M, Garc\u00eda-Sanz R, Fenton JA, Langerak AW, Gonz\u00e1lez M, van Dongen JJ, San Miguel JF, Morgan GJ. Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood. 2007;110(9):3112-21. doi: 10.1182\/blood-2007-02-069625. Epub 2007 Jul 18. PMID: 17634408.","DOI":"10.1182\/blood-2007-02-069625"},{"key":"42","doi-asserted-by":"crossref","unstructured":"Warnnissorn AN, Treetipsatit J, Limvorapitak W. The cut-offs for kappa\/lambda ratio in bone marrow immunohistochemistry for the diagnosis of multiple myeloma. Hematology. 2020;25(1):292-8.","DOI":"10.1080\/16078454.2020.1802929"},{"key":"43","doi-asserted-by":"crossref","unstructured":"Corso A, Mangiacavalli S. Non-secretory myeloma: Ready for a new definition? Mediterr J Hematol Infect Dis. 2017;9(1):e2017053.","DOI":"10.4084\/mjhid.2017.053"},{"key":"44","doi-asserted-by":"crossref","unstructured":"Stifter S, Babarovi\u0107 E, Valkovi\u0107 T, Seili-Bekafigo I, Stemberger C, Nacinovi\u0107 A, Lucin K, Jonji\u0107 N. Combined evaluation of bone marrow aspirate and biopsy is superior in the prognosis of multiple myeloma. Diagn Pathol. 2010;5:30. doi: 10.1186\/1746-1596-5-30. PMID: 20482792; PMCID: PMC2883968.","DOI":"10.1186\/1746-1596-5-30"},{"key":"45","doi-asserted-by":"crossref","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, Dimopoulos M, Kulakova M, Lam A, Hashim M, He J, Heeg B, Ukropec J, Vermeulen J, Cote S, Bahlis N. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4(23):5988-99. doi: 10.1182\/bloodadvances.2020002827. PMID: 33284948; PMCID: PMC7724898.","DOI":"10.1182\/bloodadvances.2020002827"},{"key":"46","doi-asserted-by":"crossref","unstructured":"Bertamini L, D\u00e2\u0080\u0099Agostino M, Gay F. MRD assessment in multiple myeloma: Progress and challenges. Curr Hematol Malig Rep. 2021;16(2):162-71.","DOI":"10.1007\/s11899-021-00633-5"},{"key":"47","doi-asserted-by":"crossref","unstructured":"Paiva B, Puig N, Cedena MT, Rosi\u00f1ol L, Cord\u00f3n L, Vidriales MB, Burgos L, Flores-Montero J, Sanoja-Flores L, Lopez-Anglada L, Maldonado R. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38(8):784-92. doi: 10.1200\/JCO.19.01231. Epub 2019 Nov 26. PMID: 31770060.","DOI":"10.1200\/JCO.19.01231"},{"key":"48","doi-asserted-by":"crossref","unstructured":"Flores-Montero J, Sanoja-Flores L, Paiva B, Puig N, Garcia-S\u00e1nchez O, B\u00f6ttcher S, van der Velden VHJ, P\u00e9rez-Mor\u00e1n JJ, Vidriales MB, Garc\u00eda-Sanz R, Jimenez C, Gonz\u00e1lez M, Mart\u00ednez-L\u00f3pez J, Corral-Mateos A, Grigore GE, Flux\u00e1 R, Pontes R, Caetano J, Sedek L, Del Canizo MC, Blad\u00e9 J, Lahuerta JJ, Aguilar C, B\u00e1rez A, Garc\u00eda-Mateo A, Labrador J, Leoz P, Aguilera-Sanz C, San-Miguel J, Mateos MV, Durie B, van Dongen JJM, Orfao A. Next generation flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094\u00e2\u0080\u0093103. doi: 10.1038\/leu.2017.29. Epub 2017 Jan 20. PMID: 28104919; PMCID: PMC5629369.","DOI":"10.1038\/leu.2017.29"},{"key":"49","doi-asserted-by":"crossref","unstructured":"Berger N, Kim-Schulze S, Parekh S. Minimal residual disease in multiple myeloma: Impact on response assessment, prognosis and tumor heterogeneity. Adv Exp Med Biol. 2018;1100:141-59.","DOI":"10.1007\/978-3-319-97746-1_9"},{"key":"50","doi-asserted-by":"crossref","unstructured":"Fedele PL, Willis SN, Liao Y, Low MS, Rautela J, Segal DH, Gong JN, Huntington ND, Shi W, Huang DCS, Grigoriadis G, Tellier J, Nutt SL. IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos. Blood. 2018;132(20):2166-78. doi: 10.1182\/blood-2018-05-850727. Epub 2018 Sep 18.PMID: 30228232.","DOI":"10.1182\/blood-2018-05-850727"},{"key":"51","doi-asserted-by":"crossref","unstructured":"Puertas B, Gonz\u00e1lez-Calle V, Sobejano-Fuertes E, Escalante F, Rey-Bua B, Padilla I, Garc\u00eda-Sanz R, Puig N, Guti\u00e9rrez NC, Mateos MV. Multiple myeloma with t(11;14): Impact of novel agents on outcome. Blood Cancer J. 2023;13(1):40. doi: 10.1038\/s41408-023-00807-9. PMID: 36935422; PMCID: PMC10025259.","DOI":"10.1038\/s41408-023-00807-9"},{"key":"52","doi-asserted-by":"crossref","unstructured":"Kumar SK, Harrison SJ, Cavo M, de la Rubia J, Popat R, Gasparetto C, Hungria V, Salwender H, Suzuki K, Kim I, Punnoose EA, Hong WJ, Freise KJ, Yang X, Sood A, Jalaluddin M, Ross JA, Ward JE, Maciag PC, Moreau P. Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): A randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2020;21(12):1630-42. doi: 10.1016\/S1470-2045(20)30525-8. Epub 2020 Oct 29. PMID: 33129376.","DOI":"10.1016\/S1470-2045(20)30525-8"},{"key":"53","doi-asserted-by":"crossref","unstructured":"Zielonka K, Jamroziak K. Mechanisms of resistance to venetoclax in hematologic malignancies. Adv Clin Exp Med. 2024;33(12):1421-33.","DOI":"10.17219\/acem\/181145"},{"key":"54","doi-asserted-by":"crossref","unstructured":"Tausch E, Close W, Dolnik A, Bloehdorn J, Chyla B, Bullinger L, D\u00f6hner H, Mertens D, Stilgenbauer S. Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica. 2019;104(9):e434-e437. doi: 10.3324\/haematol.2019.222588. Epub 2019 Apr 19. PMID: 31004028; PMCID: PMC6717583.","DOI":"10.3324\/haematol.2019.222588"},{"key":"55","doi-asserted-by":"crossref","unstructured":"Lasica M, Anderson MA. Review of venetoclax in CLL, AML and multiple myeloma. J Pers Med. 2021;11(6).","DOI":"10.3390\/jpm11060463"},{"key":"56","doi-asserted-by":"crossref","unstructured":"Liu J, Li S, Wang Q, Feng Y, Xing H, Yang X, Guo Y, Guo Y, Sun H, Liu X, Yang S, Mei Z, Zhu Y, Cheng Z, Chen S, Xu M, Zhang W, Wan N, Wang J, Ma Y, Zhang S, Luan X, Xu A, Li L, Wang H, Yang X, Hong Y, Xue H, Yuan X, Hu N, Song X, Wang Z, Liu X, Wang L, Liu Y. Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy. Blood. 2024;143(18):1825-36. doi: 10.1182\/blood.2023019706. PMID: 38211332; PMCID: PMC11076911.","DOI":"10.1182\/blood.2023019706"},{"key":"57","doi-asserted-by":"crossref","unstructured":"Gaballa S, Saliba RM, Srour S, Lu G, Brammer JE, Shah N, Bashir Q, Patel K, Bock F, Parmar S, Hosing C, Popat U, Delgado R, Rondon G, Shah JJ, Manasanch EE, Orlowski RZ, Champlin R, Qazilbash MH. Outcomes in patients with multiple myeloma with TP53 deletion after autologous hematopoietic stem cell transplant. Am J Hematol. 2016;91(10):E442-7. doi: 10.1002\/ajh.24487. Epub 2016 Sep 3. PMID: 27420405; PMCID: PMC5031524.","DOI":"10.1002\/ajh.24487"},{"key":"58","doi-asserted-by":"crossref","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Mart\u00ednez-L\u00f3pez J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Van Rampelbergh R, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495-505. doi: 10.1056\/NEJMoa2203478. Epub 2022 Jun 5. PMID: 35661166; PMCID: PMC10587778.","DOI":"10.1056\/NEJMoa2203478"},{"key":"59","doi-asserted-by":"crossref","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754-66. doi: 10.1056\/NEJMoa1606038. PMID: 27557302.","DOI":"10.1056\/NEJMoa1606038"},{"key":"60","doi-asserted-by":"crossref","unstructured":"Martin T, Dimopoulos MA, Mikhael J, Yong K, Capra M, Facon T, Hajek R, Spicka I, Baker R, Kim K, Martinez G, Min CK, Pour L, Leleu X, Oriol A, Koh Y, Suzuki K, Casca F, Mac\u00e9 S, Risse ML, Moreau P. Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: Updated results from IKEMA, a randomized phase 3 study. Blood Cancer J. 2023;13(1):72. doi: 10.1038\/s41408-023-00797-8. Erratum in: Blood Cancer J. 2023 Sep 27;13(1):152. doi: 10.1038\/s41408-023-00923-6. PMID: 37156782; PMCID: PMC10166682.","DOI":"10.1038\/s41408-023-00797-8"},{"key":"61","doi-asserted-by":"crossref","unstructured":"Ocio EM, Perrot A, Bories P, San-Miguel JF, Blau IW, Karlin L, Martinez-Lopez J, Wang SY, Bringhen S, Marcatti M, Mateos MV, Rodriguez-Otero P, Oliva S, Nogai A, Le Roux N, Dong L, Mac\u00e9 S, Gassiot M, Fitzmaurice T, Oprea C, Moreau P. Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible\/with no immediate intent for autologous stem cell transplantation. Leukemia. 2023;37(7):1521-9. doi: 10.1038\/s41375-023-01936-7. Epub 2023 Jun 14. PMID: 37316728; PMCID: PMC10264885.","DOI":"10.1038\/s41375-023-01936-7"},{"key":"62","doi-asserted-by":"crossref","unstructured":"Krishnan AY, Patel KK, Hari P, Jagannath S, Niesvizky R, Silbermann RW, Berg D, Lin J, Fedyk E R, Palumbo A, Stockerl-Goldstein KE. Preliminary results from a Phase 1b study of TAK-079, an investigational anti-CD38 monoclonal antibody (mAb) in patients with relapsed\/refractory multiple myeloma (RRMM). Blood. 2019;134(Suppl 1):140-.","DOI":"10.1182\/blood-2019-128007"},{"key":"63","doi-asserted-by":"crossref","unstructured":"Vogl DT, Kaufman JL, Holstein SA, Atrash S, Nadeem O, Janakiram M, Suryanarayan M, Liu Y, Collins S, Parot X, Chaudhry M. Modakafusp Alfa (TAK-573), an immunocytokine, shows clinical activity in patients with relapsed\/refractory multiple myeloma; updated results from a first-in-human Phase 1 study. Blood. 2021;138(Suppl 1):898.","DOI":"10.1182\/blood-2021-148463"},{"key":"64","doi-asserted-by":"crossref","unstructured":"De Goeij BE, Janmaat ML, Andringa G, Kil L, Van Kessel B, Frerichs KA, Lingnau A, Freidig A, Mutis T, Sasser AK, Breij EC. Hexabody-CD38, a novel CD38 antibody with a hexamerization enhancing mutation, demonstrates enhanced complement-dependent cytotoxicity and shows potent anti-tumor activity in preclinical models of hematological malignancies. Blood. 2019;134:3106.","DOI":"10.1182\/blood-2019-125788"},{"key":"65","doi-asserted-by":"crossref","unstructured":"Nijhof IS, Casneuf T, van Velzen J, van Kessel B, Axel AE, Syed K, Groen RW, van Duin M, Sonneveld P, Minnema MC, Zweegman S, Chiu C, Bloem AC, Mutis T, Lokhorst HM, Sasser AK, van de Donk NW. CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma. Blood. 2016;128(7):959-70.","DOI":"10.1182\/blood-2016-03-703439"},{"key":"66","doi-asserted-by":"crossref","unstructured":"Franssen LE, Stege CAM, Zweegman S, van de Donk N, Nijhof IS. Resistance mechanisms towards CD38-directed antibody therapy in multiple myeloma. J Clin Med. 2020;9(4).","DOI":"10.3390\/jcm9041195"},{"key":"67","doi-asserted-by":"crossref","unstructured":"Mateos MV, Bahlis N, Costa L, Perrot A, Pei L, Rubin M, Lantz K, Sun W, Jaffe M, Kobos R, Nooka A. PB2020: Majestec-3: Randomized, phase 3 study of teclistamab plus daratumumab versus DPd or DVd in patients with relapsed\/refractory multiple myeloma. Hemasphere. 2022;6(Suppl ):1891-2.","DOI":"10.1097\/01.HS9.0000850912.43010.d3"},{"key":"68","doi-asserted-by":"crossref","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodriguez-Otero P, Martinez-Lopez J, Koehne G, Touzeau C, Jethava Y, Quach H, Depaus J, Yokoyama H, Gabayan AE, Stevens DA, Nooka AK, Manier S, Raje N, Iida S, Raab MS, Searle E, Leip E, Sullivan ST, Conte U, Elmeliegy M, Czibere A, Viqueira A, Mohty M. Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results. Nat Med. 2023;29(9):2259-67.","DOI":"10.1038\/s41591-023-02528-9"},{"key":"69","doi-asserted-by":"crossref","unstructured":"Zonder JA, Richter J, Bumma N, Brayer J, Hoffman JE, Bensinger WI, Wu KL, Xu L, Chokshi D, Boyapati A, Cronier D. S189: Early, deep, and durable responses, and low rates of CRS with REGN5458, a BCMAXCD3 bispecific antibody, in a phase 1\/2 first-in-human study in patients with relapsed\/refractory multiple myeloma. HemaSphere. 2022;6:90-1.","DOI":"10.1097\/01.HS9.0000843648.44771.79"},{"key":"70","doi-asserted-by":"crossref","unstructured":"Kumar S, D'Souza A, Shah N, Rodriguez C, Voorhees PM, Bueno OF, Buelow B, Freise KJ, Yue S, Pothacamury RK, Polepally AR. Phase 1 first-in-human study of Tnb-383B, a BCMA x CD3 bispecific T-cell redirecting antibody, in patients with relapsed\/refractory multiple myeloma. Blood. 2021;138(Suppl 1):900.","DOI":"10.1182\/blood-2021-150757"},{"key":"71","doi-asserted-by":"crossref","unstructured":"Madan S, Costello CL, Lipe B, Cowan AJ, Medvedova E, Hillengass J, Bergsagel PL, Leleu X, Touzeau C, Morillo D, Oriol A, Mawad R, Schade H, Manier S, Yaron Y, Anand B, Abdallah AO. Results from the completed dose escalation portion of the Phase 1 study of HPN217, a half-life extended tri-specific T cell activating construct (TriTAC) targeting B cell maturation antigen (BCMA) for relapsed\/refractory multiple myeloma (MM). Blood. 2023;142(Suppl 1):1012.","DOI":"10.1182\/blood-2023-182345"},{"key":"72","doi-asserted-by":"crossref","unstructured":"June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64-73.","DOI":"10.1056\/NEJMra1706169"},{"key":"73","doi-asserted-by":"crossref","unstructured":"Yu S, Li A, Liu Q, Li T, Yuan X, Han X, Wu K. Chimeric antigen receptor T cells: A novel therapy for solid tumors. J Hematol Oncol. 2017;10(1):78. doi: 10.1186\/s13045-017-0444-9. PMID: 28356156; PMCID: PMC5372296.","DOI":"10.1186\/s13045-017-0444-9"},{"key":"74","doi-asserted-by":"crossref","unstructured":"Mikkilineni L, Kochenderfer JN. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol. 2021;18(2):71-84.","DOI":"10.1038\/s41571-020-0427-6"},{"key":"75","doi-asserted-by":"crossref","unstructured":"Munshi NC, Anderson LD Jr, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705-16.","DOI":"10.1056\/NEJMoa2024850"},{"key":"76","doi-asserted-by":"crossref","unstructured":"van de Donk N, Themeli M, Usmani SZ. Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma. Blood Cancer Discov. 2021;2(4):302-18.","DOI":"10.1158\/2643-3230.BCD-20-0227"},{"key":"77","doi-asserted-by":"crossref","unstructured":"Rejeski K, Jain MD, Smith EL. Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma. Transplant Cell Ther. 2023;29(7):418-28.","DOI":"10.1016\/j.jtct.2023.04.007"},{"key":"78","doi-asserted-by":"crossref","unstructured":"Atilla PA, Atilla E. Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies. Transl Oncol. 2022;22:101459.","DOI":"10.1016\/j.tranon.2022.101459"},{"key":"79","doi-asserted-by":"crossref","unstructured":"Lonial S, Lee HC, Badros A, Trudel S, Nooka AK, Chari A, Abdallah AO, Callander N, Lendvai N, Sborov D, Suvannasankha A, Weisel K, Karlin L, Libby E, Arnulf B, Facon T, Hulin C, Kort\u00fcm KM, Rodr\u00ef\u00bf\u00bdguez-Otero P, Usmani SZ, Hari P, Baz R, Quach H, Moreau P, Voorhees PM, Gupta I, Hoos A, Zhi E, Baron J, Piontek T, Lewis E, Jewell RC, Dettman EJ, Popat R, Esposti SD, Opalinska J, Richardson P, Cohen AD. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): A two-arm, randomised, open-label, phase 2 study. Lancet Oncol. 2020;21(2):207-21.","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"80","doi-asserted-by":"crossref","unstructured":"Trudel S, Lendvai N, Popat R, Voorhees PM, Reeves B, Libby EN, Richardson PG, Hoos A, Gupta I, Bragulat V, He Z, Opalinska JB, Cohen AD. Antibody-drug conjugate, GSK2857916, in relapsed\/refractory multiple myeloma: An update on safety and efficacy from dose expansion phase I study. Blood Cancer J. 2019;9(4):37. doi: 10.1038\/s41408-019-0196-6. PMID: 30894515; PMCID: PMC6426965.","DOI":"10.1038\/s41408-019-0196-6"},{"key":"81","doi-asserted-by":"crossref","unstructured":"Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I, Malandrakis P, Fotiou D, Migkou M, Theodorakakou F, Spiliopoulou V, Kostopoulos IV, Syrigou RE, Eleutherakis-Papaiakovou E, Gkolfinopoulos S, Tsitsilonis OE, Kastritis E, Dimopoulos MA. Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Part 1 results of a phase I\/II study. Haematologica. 2024;109(8):2594-605.","DOI":"10.3324\/haematol.2023.284347"},{"key":"82","doi-asserted-by":"crossref","unstructured":"Mor\u00e8 S, Offidani M, Corvatta L, Petrucci MT, Fazio F. Belantamab mafodotin: From clinical trials data to real-life experiences. Cancers. 2023;15(11):2948.","DOI":"10.3390\/cancers15112948"},{"key":"83","doi-asserted-by":"crossref","unstructured":"Ray U, Orlowski RZ. Antibody-drug conjugates for multiple myeloma: Just the beginning, or the beginning of the end? Pharmaceuticals. 2023;16(4).","DOI":"10.3390\/ph16040590"},{"key":"84","doi-asserted-by":"crossref","unstructured":"Allegra A, Tonacci A, Sciaccotta R, Genovese S, Musolino C, Pioggia G, Gangemi S. Machine learning and deep learning applications in multiple myeloma diagnosis, prognosis, and treatment selection. Cancers. 2022;14(3):606. doi: 10.3390\/cancers14030606. PMID: 35158874; PMCID: PMC8833500.","DOI":"10.3390\/cancers14030606"}],"container-title":["Critical Reviews in Eukaryotic Gene Expression"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dl.begellhouse.com\/download\/article\/3e9cd4b42a5c932c\/CRE-60495.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T07:58:15Z","timestamp":1765958295000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dl.begellhouse.com\/journals\/6dbf508d3b17c437,22b25596365788b3,3e9cd4b42a5c932c.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":83,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1615\/critreveukaryotgeneexpr.2025060495","relation":{},"ISSN":["1045-4403"],"issn-type":[{"type":"print","value":"1045-4403"}],"subject":[],"published":{"date-parts":[[2025]]}}}